Evidence map›Paper›PMID 30446932›Full record

SynthesisHepatology international2019

The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Zhongcao Wei, Na Liu, Xinxing Tantai, Xin Xing, Cailan Xiao, Lirong Chen, Jinhai Wang

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Hepatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 6 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 6 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhongcao WeiDepartment of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China.
Na LiuDepartment of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China. liunafmmu@163.com.
Xinxing TantaiDepartment of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China.
Xin XingDepartment of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China.
Cailan XiaoDepartment of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China.
Lirong ChenDepartment of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China.
Jinhai WangDepartment of Gastroenterology, The Second Affiliated Hospital, Xi'an Jiaotong University, No. 157, Xi Wu Road, Xi'an, Shanxi, People's Republic of China. jinhaiwang@hotmail.com.
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsEvidence indicates that curcumin seems to improve outcomes in non-alcoholic fatty liver disease (NAFLD). A meta-analysis was performed to evaluate the effects of curcumin inNAFLD.

methodsWe searched PubMed, EMBASE, and the Cochrane Library from inception through March 2018 to identify randomized controlled trials (RCTs) evaluating the role of curcumin inNAFLD. The mean difference (MD) and 95% confidence interval (CI) were calculated.

resultsFour RCTs with a total of 229 NAFLD patients were included. Curcumin was more likely to lower LDL-C, triglycerides, FBS, HOMA-IR, weight and AST levels compared with placebo, and the difference was statistically significant [MD = - 27.02, 95% CI (- 52.30, - 1.74); MD = - 33.20, 95% CI (- 42.30, - 24.09); MD = - 5.63, 95% CI (- 10.36, - 0.90); MD = - 0.53, 95% CI (- 1.00, - 0.05); MD = - 2.27, 95% CI (- 3.11, - 1.44); MD = - 7.43, 95% CI (- 11.31, - 3.54), respectively]. However, the beneficial effect of curcumin did not achieve statistical significance in lowering total cholesterol, HDL-C, HbA1c, ALT or insulin levels [MD = - 30.47,95% CI (- 60.89. - 0.06); MD = - 0.98, 95% CI (- 2.88, 0.92); MD = - 0.41, 95% CI (- 1.41, 0.59); MD = - 6.02, 95% CI (- 15.61, 3.57); MD = - 0.92, 95% CI (- 2.33, 0.49)].

conclusionsCurcumin is effective in lowering LDL-C, triglycerides, FBS, HOMA-IR, weight, and AST levels in NAFLD patients, and it is well tolerated. Further RCTs are required to confirm our findings.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalCurcuminHumansNon-alcoholic Fatty Liver DiseaseRandomized Controlled Trials as TopicAnti-Inflammatory Agents, Non-SteroidalCurcuminCurcuminMeta-analysisNon-alcoholic fatty liver disease

Identifiers

PMID30446932
OpenAlexW2901732373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.